Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.55 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2821116 | 0.98 | HCAR3 (0.54) | HCAR3P4HA1P4HTMMAPTMIF | |
| SCHEMBL27810972 | 0.98 | HCAR3 (0.54) | HCAR3P4HA1P4HTMMAPTMIF | |
| SCHEMBL12412592 | 0.87 | KMT2A (0.45) | HCAR3MAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL19876773 | 0.85 | P4HA1 (0.53) | HCAR3P4HA1P4HTMMAPTMIF | |
| SCHEMBL2706310 | 0.81 | ALDH1A1 (0.46) | HCAR3MAPTALDH1A1CYP1A2HPGD | |
| SCHEMBL250023 | 0.81 | MAPK1 (0.56) | MAPTALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL344135 | 0.79 | MAPT (0.58) | HCAR3P4HA1P4HTMMAPTMIF | |
| SCHEMBL6351750 | 0.79 | CA12 (0.47) | MAPTALDH1A1CYP1A2CYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL27647127 | 0.78 | MAPT (0.56) | HCAR3P4HA1P4HTMMAPTMIF | |
| SCHEMBL2847467 | 0.78 | HCAR3 (0.48) | HCAR3P4HA1P4HTMMAPTMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8012998-B2 | Pyrrolidine aryl-ether as NK-3 receptor antagonists | Hoffmann—La Roche Inc. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2185540-B1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| CN-101778837-A | Pyrrolidine aryl-ether as nk3 receptor antagonists | HOFFMANN LA ROCHE | 2010-07-14 | — | — | CN | disclosed |
| EP-2185540-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2009019163-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | HCAR3 1748/4885P4HA1 446/4885P4HTM 1362/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | HCAR3 1748/4885P4HA1 446/4885P4HTM 1362/4885 |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | HCAR3 231/4885P4HA1 601/4885P4HTM 1232/4885 |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | HCAR3 463/4885P4HA1 1028/4885P4HTM 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.